This acquisition strengthens Nemera’s proprietary product offering and establishes operations footprint in Eastern Europe.
Nemera today announced that they have entered into an agreement to acquire Copernicus. Copernicus, based in Szczecin Poland, specializes in the development and manufacturing of injection devices. Their range of reusable and disposable pen injectors are tailored for the treatment of several chronic pathologies.
Founded in 2004, Copernicus is regarded as one of the most valued innovative companies in the Polish health sector. They provide a comprehensive range of services in the introduction of modern and intuitive parenteral drug delivery devices.
This acquisition reinforces Nemera’s vision of becoming the most patient-centric drug device combination solutions company. It bolsters our small series production capabilities, R&D expertise and parenteral product offering. Most importantly it expands our overall proprietary product portfolio. Copernicus’ fast and agile clinical manufacturing, adapted for small series, complements Nemera’s historical large scale manufacturing capabilities. Furthermore, Copernicus’ marketed reusable pen injectors are of great value from a sustainability standpoint.
With this acquisition we establish an operations footprint in Eastern Europe. In order to accompany Copernicus’ solid forecasted growth we will work together to build a new state-of-the-art manufacturing facility in Szczecin, Poland.
Marc Hämel, CEO of Nemera said, “This acquisition is a great strategic and cultural fit for us. Copernicus’ strong focus on patient needs aligns perfectly with our purpose of always putting the patient at the center of everything we do. We’re about to write a new chapter of Nemera’s growth story and I’m really excited about our bright future”.
“Nemera’s unaltered focus on patient needs and passion to develop combination product solutions of the future convinced us that this was the right next step. We’re thrilled to join Nemera and together make products that truly improve patients’ lives” added Alberto Lozano, CEO of Copernicus.